Several changes took place within Editorial Board of Vox Sanguinis during the year. In February 2025, Nancy M. Dunbar informed me of her wish to step down as Editor of the International Forum (IF) section at the end of the year. This advance notice provided sufficient time to identify an appropriate successor. Following consultation with the Vox Sanguinis Standing Committee, Arwa Z. Al‐Riyami from Oman, was appointed as the new Editor of the IF section. After several months of close collaboration with Nancy, to ensure a smooth transition, she officially assumed the role in January 2026.

In addition, Leo van de Watering, stepped down as Section Editor of the Review Section in November 2025, coinciding with the migration to Research Exchange, the Wiley’s platform for managing manuscript submission and peer review. Taking advantage of this transition, a re organization of the Review section was undertaken. It was considered preferable that review articles be handled directly by the Section Editors of the relevant subject areas, rather than by a dedicated Review Section Editor. Following discussion, Dr. Szczepiorkowski agreed to this proposal. Consequently, the Review Section was discontinued, and he resumed responsibility solely for the Cellular Therapy section.

The remaining members of the Editorial Board, remained unchanged: Blood Component Collection and Production: Denese Marks (Sydney, Australia); Donors and Donations: Katja van den Hurk (Amsterdam, the Netherlands); Haemovigilance: Claudia S. Cohn (Minneapolis, MN, USA); Immunohaematology and Immunogenetics: Jill R. Storry (Lund, Sweden); Patient Blood Management: Nelson H. Tsuno (Tokyo, Japan); Transfusion Medicine and New Therapies: Pierre Tiberghien; and Transfusion‐Transmitted Disease and its Prevention: Sheila O’Brien (Ottawa, Canada).

Miquel Lozano continues to serve as Editor‐in‐Chief.

Maria Davie, who had served as Technical Editor of Vox Sanguinis since February 2021, stepped down from her position on February 23, 2025. She recommended Louise Robb as her successor. Louise had previously worked with Maria at Wiley’s Edinburgh office, which operated until 2010. Following deliberations with the ISBT Standing Committee, Louise Robb assumed the role of Technical Editor on February 23, 2025. A transition period of several weeks, during which she worked closely with Maria, ensured a smooth handover of responsibilities.

Claire Dowbekin has continued in her as Journal Publishing Manager at Wiley and Thomas Sinden as Wiley representative responsible for the economic aspects of the relationship between Wiley and ISBT.

On November 17, 2025, Vox Sanguinis migrated from Scholar One, which had been used for many years to manage submissions and peer review, to Research Exchange (ReX), a manuscript management system developed by Wiley.

Contrary to initial expectations regarding flexibility and customization, the current experience with ReX has been challenging. Several requested functionalities have not yet been implemented, even five months after submission of these requests.

The most conspicuous issue is illustrated in Annex 1. Among the reasons available for declining a submitted manuscript, there is no option to indicate that a manuscript was given low priority for publication (Annex 1, page 1)—a reason that would help avoid unnecessary discussion with authors regarding the quality or novelty of their work. As a result, the system generates the following generic and awkward message (Annex 1, page 2):

Unfortunately, they have found it unsuitable for consideration in Vox Sanguinis for the following reason(s)

• The manuscript was found to be unsuitable for this journal

Moreover, the software does not allow any modification of this automatically generated text.